As expected, knockdown of Twist1 alleviated the distinct expression levels of mesenchymal makers between glioma cells upon NE treatment and DMSO treatment (Fig. 5C&D, One-way ANOVA, U251, N-cadherin p = 0.014, Fibronectin p = 0.016, Vimentin p = 0.021; LN229, N-cadherin p = 0.037, Fibronectin p = 0.011, Vimentin p = 0.008). Here, TWIST1 is linked to central nervous system cancer.